Absorption, Distribution and Excretion
(1-Dodecyl-14C) laurylamine oxide (10 mg, containing 100 μCi 14C) was applied to the skin of two human subjects to investigate skin absorption and metabolism of laurylamine oxide. Eight hours after administration, 92% of the radioactive material was recovered from the subjects' skin, and 0.1% and 0.23% of the radioactive material were recovered from their excrement, respectively. The radioactive material content in the stratum corneum was less than 0.2%. Oral administration of a solution containing 50 mg of (1-Dodecyl-14C) laurylamine oxide (containing 100 μCi 14C) to two subjects showed that the excretion pattern of the radioactive material was similar to that of other study species. Within 24 hours after administration, 50% to 37% of the radioactive material was detected in urine, while 18% to 22% of the administered radioactive material was found in exhaled CO2. Four Sprague-Dawley rats were intraperitoneally injected with 22 mg/kg of (methyl-14C) laurylamine oxide (specific activity 1.3 mCi/g). Within 24 hours, 67% of the total radioactive material was excreted in the urine, 8% in the form of 14C CO2, and 6% in the feces. The radioactive distribution was essentially the same as that in rats orally administered laurylamine oxide. The conclusion was: "...the microbial metabolism of the gastrointestinal flora does not play a major role in the absorption and excretion of [laurylamine oxide] in rats." An aqueous solution of (methyl-14C) laurylamine oxide (10 mg, containing 1.3 mCi/g) was applied to the skin of four Sprague-Dawley rats to test the metabolism and absorption of this compound. After 72 hours, 14.2% of the total radioactivity was detected in the urine, 2.5% in the carbon dioxide, and 1.8% in the feces. Radioactivity was detected in the liver, kidneys, testes, blood, and exhaled carbon dioxide. For more complete data on the absorption, distribution, and excretion of laurylamine oxides (7 in total), please visit the HSDB record page. Metabolites/Metabolites: Metabolic profiles across different species (rats, humans, mice, rabbits) showed no significant differences in metabolites, but the extent of absorption, particularly with transdermal administration, varied by species. Characterization of laurylamine oxide metabolites identified only one metabolite, N-dimethyl-4-aminobutyric acid N-oxide. Laurylamine oxides have multiple metabolic pathways: ω,β-oxidation of alkyl chains (the most common pathway in surfactant metabolism), hydroxylation of alkyl chains, and reduction of amine oxide groups. Urinary metabolites from rats, rabbits, and humans indicate that the metabolic pathway includes ω,β-oxidation of adipose chains, reduction of amine oxides, and hydroxylation of the mid-chain of adipose chains. The contents of N,N-dimethyl-4-aminobutyric acid and its N-oxide in humans, rats and rabbits were 28%, 28% and 23%, respectively.

Dimethyldodecylamine-N-oxide is a crystalline solid. Dodecyl dimethylamine-N-oxide is a tertiary amine oxide, formed by the oxidation of the amino group of dodecyl dimethylamine. It is a plant metabolite and surfactant. It is derived from the hydride of dodecane. Laurylamine oxide has been reportedly found in Euglena gracilis, and relevant data are available.

C14H31NO

229.408

229.24

1643-20-5

15433

Very hygroscopic needles from dry toluene.

0.996 g/mL at 20ºC

100ºC

132-133ºC

94ºC

6.88E-05mmHg at 25°C

n20/D 1.378

3.27

0

1

11

16

146

0

CCCCCCCCCCCC[N+](C)(C)[O-]

SYELZBGXAIXKHU-UHFFFAOYSA-N

InChI=1S/C14H31NO/c1-4-5-6-7-8-9-10-11-12-13-14-15(2,3)16/h4-14H2,1-3H3

N,N-dimethyldodecan-1-amine oxide

Dimethylaurylamine oxide; Refan; Lauramine oxide

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~100 mg/mL (~435.92 mM)

Solubility in Formulation 1: ≥ 2.5 mg/mL (10.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (10.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (10.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)